Atrinsic (PTIX)
(Delayed Data from NSDQ)
$1.26 USD
-0.03 (-2.34%)
Updated Apr 22, 2024 09:41 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PTIX 1.26 -0.03(-2.34%)
Will PTIX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PTIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for PTIX
Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
Earnings Scheduled For April 1, 2024
Protagenic Therapeutics GAAP EPS of -$1.15